These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19686691)

  • 1. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
    Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
    Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.
    Fonseca JA; McCaffery JN; Kashentseva E; Singh B; Dmitriev IP; Curiel DT; Moreno A
    Vaccine; 2017 May; 35(24):3239-3248. PubMed ID: 28483199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
    Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
    PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.
    Ishizuka AS; Lyke KE; DeZure A; Berry AA; Richie TL; Mendoza FH; Enama ME; Gordon IJ; Chang LJ; Sarwar UN; Zephir KL; Holman LA; James ER; Billingsley PF; Gunasekera A; Chakravarty S; Manoj A; Li M; Ruben AJ; Li T; Eappen AG; Stafford RE; K C N; Murshedkar T; DeCederfelt H; Plummer SH; Hendel CS; Novik L; Costner PJ; Saunders JG; Laurens MB; Plowe CV; Flynn B; Whalen WR; Todd JP; Noor J; Rao S; Sierra-Davidson K; Lynn GM; Epstein JE; Kemp MA; Fahle GA; Mikolajczak SA; Fishbaugher M; Sack BK; Kappe SH; Davidson SA; Garver LS; Björkström NK; Nason MC; Graham BS; Roederer M; Sim BK; Hoffman SL; Ledgerwood JE; Seder RA
    Nat Med; 2016 Jun; 22(6):614-23. PubMed ID: 27158907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Shears MJ; Watson FN; Stone BC; Cruz Talavera I; Parthiban C; Matsubara J; Kc N; Sim BKL; Hoffman SL; Murphy SC
    Vaccine; 2023 Aug; 41(38):5494-5498. PubMed ID: 37563050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.
    Capone S; Meola A; Ercole BB; Vitelli A; Pezzanera M; Ruggeri L; Davies ME; Tafi R; Santini C; Luzzago A; Fu TM; Bett A; Colloca S; Cortese R; Nicosia A; Folgori A
    J Virol; 2006 Feb; 80(4):1688-99. PubMed ID: 16439526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective induction of high-titer antibodies by viral vector vaccines.
    Draper SJ; Moore AC; Goodman AL; Long CA; Holder AA; Gilbert SC; Hill F; Hill AV
    Nat Med; 2008 Aug; 14(8):819-21. PubMed ID: 18660818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.
    Ogwang C; Kimani D; Edwards NJ; Roberts R; Mwacharo J; Bowyer G; Bliss C; Hodgson SH; Njuguna P; Viebig NK; Nicosia A; Gitau E; Douglas S; Illingworth J; Marsh K; Lawrie A; Imoukhuede EB; Ewer K; Urban BC; Hill AVS; Bejon P;
    Sci Transl Med; 2015 May; 7(286):286re5. PubMed ID: 25947165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
    Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
    J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen.
    Rais M; Abdelaal H; Reese VA; Ferede D; Larsen SE; Pecor T; Erasmus JH; Archer J; Khandhar AP; Cooper SK; Podell BK; Reed SG; Coler RN; Baldwin SL
    Tuberculosis (Edinb); 2023 Jan; 138():102302. PubMed ID: 36586154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention.
    Kisalu NK; Pereira LD; Ernste K; Flores-Garcia Y; Idris AH; Asokan M; Dillon M; MacDonald S; Shi W; Chen X; Pegu A; Schön A; Zavala F; Balazs AB; Francica JR; Seder RA
    JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33332286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine.
    MacMillen Z; Hatzakis K; Simpson A; Shears MJ; Watson F; Erasmus JH; Khandhar AP; Wilder B; Murphy SC; Reed SG; Davie JW; Avril M
    NPJ Vaccines; 2024 Jan; 9(1):12. PubMed ID: 38200025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine.
    MacMillen Z; Hatzakis K; Simpson A; Shears M; Watson F; Erasmus J; Khandhar A; Wilder B; Murphy S; Reed S; Davie J; Avril M
    Res Sq; 2023 Jun; ():. PubMed ID: 37461621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine.
    MacMillen Z; Hatzakis K; Simpson A; Shears MJ; Watson F; Erasmus JH; Khandhar AP; Wilder B; Murphy SC; Reed SG; Davie JW; Avril M
    bioRxiv; 2023 May; ():. PubMed ID: 37292739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.
    Colloca S; Barnes E; Folgori A; Ammendola V; Capone S; Cirillo A; Siani L; Naddeo M; Grazioli F; Esposito ML; Ambrosio M; Sparacino A; Bartiromo M; Meola A; Smith K; Kurioka A; O'Hara GA; Ewer KJ; Anagnostou N; Bliss C; Hill AV; Traboni C; Klenerman P; Cortese R; Nicosia A
    Sci Transl Med; 2012 Jan; 4(115):115ra2. PubMed ID: 22218691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination.
    Watson FN; Shears MJ; Matsubara J; Kalata AC; Seilie AM; Cruz Talavera I; Olsen TM; Tsuji M; Chakravarty S; Sim BKL; Hoffman SL; Murphy SC
    Am J Trop Med Hyg; 2022 Apr; 106(4):1227-1236. PubMed ID: 35226868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy.
    Flickinger JC; Staudt RE; Singh J; Carlson RD; Barton JR; Baybutt TR; Rappaport JA; Zalewski A; Pattison A; Waldman SA; Snook AE
    NPJ Vaccines; 2022 Jun; 7(1):61. PubMed ID: 35739202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.
    Brown SA; Surman SL; Sealy R; Jones BG; Slobod KS; Branum K; Lockey TD; Howlett N; Freiden P; Flynn P; Hurwitz JL
    Viruses; 2010 Feb; 2(2):435-467. PubMed ID: 20407589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian inference for prediction of survival probability in prime-boost vaccination regimes.
    Lu Y; Carlin BP; Seaman JW
    Stat Med; 2024 Feb; 43(3):560-577. PubMed ID: 38109707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging cancer vaccines: the promise of genetic vectors.
    Aurisicchio L; Ciliberto G
    Cancers (Basel); 2011 Sep; 3(3):3687-713. PubMed ID: 24212974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.